572
Participants
Start Date
November 5, 2020
Primary Completion Date
December 20, 2025
Study Completion Date
December 20, 2025
brolucizumab
There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Neubrandenburg
Novartis Investigative Site, Waren
Novartis Investigative Site, Rostock
Novartis Investigative Site, Stralsund
Novartis Investigative Site, Kiel
Novartis Investigative Site, Göttingen
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Schönebeck
Novartis Investigative Site, Münster
Novartis Investigative Site, Osnabrück
Novartis Investigative Site, Cologne
Novartis Investigative Site, Bonn
Novartis Investigative Site, Trier
Novartis Investigative Site, Frankfurt am Main
Novartis Investigative Site, Hösbach
Novartis Investigative Site, Saarbrücken
Novartis Investigative Site, Sulzbach
Novartis Investigative Site, Homburg
Novartis Investigative Site, Esslingen am Neckar
Novartis Investigative Site, Breisach
Novartis Investigative Site, München
Novartis Investigative Site, Neuburg am Inn
Novartis Investigative Site, Bayreuth
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Schneeberg
Novartis Investigative Site, Halle
Novartis Investigative Site, Aschersleben
Novartis Investigative Site, Chemnitz
Novartis Investigative Site, Dresden
Novartis Investigative Site, Dresden
Novartis Investigative Site, Dresden
Novartis Investigative Site, Glauchau
Novartis Investigative Site, Jena
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Marienberg
Novartis Investigative Site, Torgau
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY